<DOC>
	<DOCNO>NCT02860286</DOCNO>
	<brief_summary>This Phase 2 , multicenter , open-label , 2-part , single-arm , 2-stage study tazemetostat 800 mg two time day ( BID ) administer orally . Screening subject determine eligibility study perform within 21 day first plan dose tazemetostat . In Part 1 , 12 subject relapse refractory malignant mesothelioma regardless BAP1 status treat undergo pharmacokinetics ( PK ) blood sample collection single tazemetostat 800 mg. Part 2 include subject BAP1-deficient relapse refractory malignant mesothelioma . Treatment tazemetostat continue disease progression , unacceptable toxicity withdrawal consent , termination study . Response assessment evaluate 6 week treatment every 12 week thereafter study .</brief_summary>
	<brief_title>Study EZH2 Inhibitor Tazemetostat Malignant Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>1 . Age ( time consent ) ≥18 year age 2 . Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 3 . Has life expectancy &gt; 3 month 4 . Has mesothelioma ( pleural , peritoneal , pericardial , tunica vaginalis ) histology relapse refractory treatment least one pemetrexedcontaining regimen 5 . Has document local diagnostic pathology original biopsy confirm Clinical Laboratory Improvement Amendments ( CLIA ) /College American Pathologists ( CAP ) equivalent laboratory certification 6 . Part 2 : Molecular evidence BAP1 loss function mutation present local pathology , e.g. , lack nuclear BAP1 stain immunohistochemistry ( IHC ) evidence loss function gene sequence 7 . Has sufficient archival tumor tissue ( minimum 10 slide tumor block ) available central retrospective test BAP1 status 8 . Has prior treatment ( i.e. , chemotherapy , immunotherapy , radiotherapy ) relate clinically significant toxicity resolve ≤ Grade 1 per CTCAE , version 4.03 clinically stable clinically significant , time enrollment 9 . Prior therapy ( y ) , applicable , must complete accord criterion prior first dose tazemetostat : Cytotoxic chemotherapy ; least 21 day since last dose Noncytotoxic chemotherapy ( e.g. , small molecule inhibitor ) ; least 14 day since last dose Monoclonal antibody ; least three halflives since last dose Nonantibody immunotherapy ( e.g. , tumor vaccine ) ; least 42 day since last dose Radiotherapy , least 14 day last local site radiotherapy Hematopoietic growth factor ; least 14 day last dose Investigational drug ; 30 day five halflives , whichever long , last dose 10 . Has measurable disease base either modified RECIST [ Nowak 2005 ] thoracic disease RECIST 1.1 elsewhere 11 . Has adequate hematologic ( bone marrow coagulation factor ) , renal , hepatic function define criterion : Hemoglobin ≥9 mg/dL Platelets ≥100,000/mm3 ( ≥100 × 109/L ) without platelet transfusion 7 day ANC ≥1000/mm3 ( ≥1.0 × 109/L ) without growth factor support 14 day Coagulation : Prothrombin time ( PT ) &lt; 1.5 × ULN partial thromboplastin time ( PTT ) &lt; 1.5 × ULN Creatinine &lt; 2.0 × ULN Hepatic function : Conjugated bilirubin &lt; 1.5 × ULN ALT AST &lt; 3 × ULN 12 . Has QT interval correct Fridericia 's formula ( QTcF ) ≤480 msec 13 . Willing provide tissue translational research 14 . Female subject childbearing potential must negative urine serum pregnancy within 72 hour prior receive first dose study drug ; urine test positive confirm negative , serum pregnancy test require subject also agree use adequate method contraception start screen 30 day last dose study therapy ( sexually active ) . 15 . Male subject agree use condom start first dose study therapy 30 day last dose study therapy sexually active female childbearing potential 1 . Has prior exposure tazemetostat inhibitor ( ) enhancer zeste homologue2 ( EZH2 ) 2 . Has history know central nervous system metastasis 3 . Has prior malignancy malignancy study Exception : A subject diseasefree 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . 4 . Has major surgery within 3 week prior enrollment ( percutaneous biopsy , pleural catheter insertion , placement central venous catheter minor procedure permit ) 5 . Is unwilling exclude grapefruit juice , Seville oranges grapefruit diet food contain fruits time enrollment throughout time study 6 . Has cardiovascular impairment , history congestive heart failure great NYHA Class II , uncontrolled arterial hypertension , unstable angina , myocardial infarction , stroke within 6 month prior plan first dose tazemetostat ; ventricular cardiac arrhythmia require medical treatment 7 . Is currently take prohibit medication ( ) 8 . Has active infection require systemic treatment 9 . Has congenital acquire immunodeficiency , include subject know history infection human immunodeficiency virus ( HIV ) NOTE : HIVpositive subject take antiretroviral therapy ineligible due potential PK interaction tazemetostat . 10 . Has know history chronic infection hepatitis B virus ( hepatitis B surface antigen positive ) hepatitis C virus ( detectable antihepatitis C circulate viral RNA ) 11 . Has deep venous thrombosis ( DVT ) pulmonary embolism within 3 month prior study enrollment . NOTE : Subjects history DVT pulmonary embolism &gt; 3 month prior study enrollment anticoagulation therapy low molecular weight heparin eligible study . 12 . Is pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>